Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Chemomab Therapeutics Ltd. (CMMB)

Chemomab names Sigal Fattal CFO; sets $260,000 salary and 45% bonus target

Neutral Impact 3 of 5 leadership Written later

Chemomab Therapeutics appointed Sigal Fattal, its former VP of Finance, as Chief Financial Officer on June 1, 2023, and the Board approved her compensation on June 14, 2023. The package includes a $260,000 base salary, a bonus potential of 45% of base salary tied to objectives yet to be set, and options on 102,860 ADSs at $1.70 that vest over four years.

Key points

  • Appointed Sigal Fattal as Chief Financial Officer on June 1, 2023; she previously served as VP of Finance
  • Annual base salary of $260,000, plus a bonus potential of 45% of base salary
  • Options to buy 102,860 American Depositary Shares at $1.70, vesting over four years, with acceleration on a change in control

The filing

CompanyChemomab Therapeutics Ltd. (CMMB)
Form8-K, current report
Filed with the SECJun 16, 2023, 4:01 PM ET
Accession number0001178913-23-002225

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 16, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.